Login to Your Account



Endo to Acquire Penwest for $168M, Cutting Royalty Stream

By Catherine Hollingsworth


Wednesday, August 11, 2010
Penwest Pharmaceuticals Co. said that Endo Pharmaceuticals Inc., its longtime partner for pain drug Opana ER, has agreed to acquire all the common stock of Penwest for $5 per share in cash, in a deal worth approximately $168 million in total equity value. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription